Publications 2023
[Not Available]
Tidsskr Nor Laegeforen, 143 (3)
DOI 10.4045/tidsskr.22.0762, PubMed 36811432
Governing by commissioning services - Implementing alcohol screening and brief interventions in hospital settings in Norway
Eval Program Plann, 98, 102271
DOI 10.1016/j.evalprogplan.2023.102271, PubMed 36921405
[Not Available]
Tidsskr Nor Laegeforen, 143 (5)
DOI 10.4045/tidsskr.22.0471, PubMed 36987889
Transition From Substance-Induced Psychosis to Schizophrenia Spectrum Disorder or Bipolar Disorder
Am J Psychiatry, 180 (6), 437-444
DOI 10.1176/appi.ajp.22010076, PubMed 37132221
Publications 2022
The relationships between use of alcohol, tobacco and coffee in adolescence and mood disorders in adulthood
Acta Psychiatr Scand, 146 (6), 594-603
DOI 10.1111/acps.13506, PubMed 36177725
PriSUD-Nordic-Diagnosing and Treating Substance Use Disorders in the Prison Population: Protocol for a Mixed Methods Study
JMIR Res Protoc, 11 (3), e35182
DOI 10.2196/35182, PubMed 35320114
Group treatment for complex dissociative disorders: a randomized clinical trial
BMC Psychiatry, 22 (1), 338
DOI 10.1186/s12888-022-03970-8, PubMed 35578194
Concentrations of psychoactive substances in blood samples from non-fatal and fatal opioid overdoses
Br J Clin Pharmacol, 88 (10), 4494-4504
DOI 10.1111/bcp.15365, PubMed 35470456
The effect of employment support integrated in substance use treatment: A health economic cost-effectiveness simulation of three different interventions
Nordisk Alkohol Nark, 40 (2), 199-211
DOI 10.1177/14550725221122196, PubMed 37063816
Annual incidence of substance-induced psychoses in Scandinavia from 2000 to 2016
Psychol Med, 1-10 (in press)
DOI 10.1017/S003329172200229X, PubMed 35983644
Avoidant and borderline personality disorder patients during the first Covid-19 wave in Norway - a survey-based comparison of therapy changes and patients' accommodations
Nord J Psychiatry, 77 (4), 336-344
DOI 10.1080/08039488.2022.2110614, PubMed 35984379
Publications 2021
Stabilizing group treatment for childhood-abuse related PTSD: a randomized controlled trial
Eur J Psychotraumatol, 12 (1), 1859079
DOI 10.1080/20008198.2020.1859079, PubMed 33537118
Vulnerability of personality disorder during the Covid-19 crises - a multicenter survey of treatment experiences among patients referred to treatment
Nord J Psychiatry, 76 (1), 52-63
DOI 10.1080/08039488.2021.1934110, PubMed 34126854
Smoking in early adulthood is prospectively associated with prescriptions of antipsychotics, mood stabilizers, antidepressants and anxiolytics
Psychol Med, 52 (14), 3241-3250
DOI 10.1017/S0033291720005401, PubMed 33583454
The effect evaluation of Individual Placement and Support (IPS) for patients with substance use disorders: study protocol for a randomized controlled trial of IPS versus enhanced self-help
Trials, 22 (1), 705
DOI 10.1186/s13063-021-05673-z, PubMed 34654464
Publications 2020
Corrigendum to "Drop-out from addiction treatment: A systematic review of risk factors"
Clin Psychol Rev, 76, 101796
DOI 10.1016/j.cpr.2019.101796, PubMed 32067823
Factors associated with drug use in prison - results from the Norwegian offender mental health and addiction (NorMA) study
Health Justice, 8 (1), 10
DOI 10.1186/s40352-020-00112-8, PubMed 32399643
Complementary horse-assisted therapy for substance use disorders: a randomized controlled trial
Addict Sci Clin Pract, 15 (1), 7
DOI 10.1186/s13722-020-0183-z, PubMed 32019584
Use of anabolic-androgenic steroids and other substances prior to and during imprisonment - Results from the Norwegian Offender Mental Health and Addiction (NorMA) study
Drug Alcohol Depend, 217, 108255
DOI 10.1016/j.drugalcdep.2020.108255, PubMed 32949884
Unrestricted use of polymer-free sirolimus eluting stents in routine clinical practice
Medicine (Baltimore), 99 (8), e19119
DOI 10.1097/MD.0000000000019119, PubMed 32080086
Polymer-free sirolimus-eluting stent use in Europe and Asia: Ethnic differences in demographics and clinical outcomes
PLoS One, 15 (1), e0226606
DOI 10.1371/journal.pone.0226606, PubMed 31929543
A multi-center psychometric evaluation of the Severity Indices of Personality Problems 118 (SIPP-118): Do we really need all those facets?
Qual Life Res, 30 (2), 567-575
DOI 10.1007/s11136-020-02654-8, PubMed 33029679
Quality of life among patients seeking treatment for substance use disorder, as measured with the EQ-5D-3L
J Patient Rep Outcomes, 4 (1), 92
DOI 10.1186/s41687-020-00247-0, PubMed 33165764
Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone
Addiction, 116 (8), 2084-2093
DOI 10.1111/add.15378, PubMed 33338285
Effect of Self-Efficacy on Quality of Life in People With Mild Cognitive Impairment and Mild Dementia: The Mediating Roles of Depression and Anxiety
Am J Alzheimers Dis Other Demen, 35, 1533317519885264
DOI 10.1177/1533317519885264, PubMed 31916847
Managing depressive symptoms in people with mild cognitive impairment and mild dementia with a multicomponent psychotherapy intervention: a randomized controlled trial
Int Psychogeriatr, 33 (3), 217-231
DOI 10.1017/S1041610220000216, PubMed 32131911
Publications 2019
Measuring Personality Problems in Patients With Substance Use Disorders: A Cross-Sample Validation
J Dual Diagn, 15 (4), 324-332
DOI 10.1080/15504263.2019.1668583, PubMed 31571533
Predicting Dropout from Inpatient Substance Use Disorder Treatment: A Prospective Validation Study of the OQ-Analyst
Subst Abuse, 13, 1178221819866181
DOI 10.1177/1178221819866181, PubMed 31452601
Anabolic androgenic steroid dependence is associated with impaired emotion recognition
Psychopharmacology (Berl), 236 (9), 2667-2676
DOI 10.1007/s00213-019-05239-7, PubMed 30941469
Treating Patients With Co-occurring Autism Spectrum Disorder and Substance Use Disorder: A Clinical Explorative Study
Subst Abuse, 13, 1178221819843291
DOI 10.1177/1178221819843291, PubMed 31024216
Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study
JAMA Psychiatry, 76 (2), 127-134
DOI 10.1001/jamapsychiatry.2018.3537, PubMed 30566177
No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study
Am J Addict, 28 (2), 77-85
DOI 10.1111/ajad.12859, PubMed 30701613
Psychometric Properties of the Severity Indices of Personality Problems (SIPP) in Two Samples A Norwegian Community Sample and Clinical Samples of Patients With and Without Personality Disorders
Eur. J. Psychol. Assess., 35 (5), 698-711
DOI 10.1027/1015-5759/a000436
Cannabis use in early adulthood is prospectively associated with prescriptions of antipsychotics, mood stabilizers, and antidepressants
Acta Psychiatr Scand, 141 (2), 149-156
DOI 10.1111/acps.13104, PubMed 31560790
Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial
Eur Addict Res, 25 (6), 303-309
DOI 10.1159/000501931, PubMed 31340204
The Montreal Cognitive Assessment as a predictor of dropout from residential substance use disorder treatment
Heliyon, 5 (3), e01282
DOI 10.1016/j.heliyon.2019.e01282, PubMed 31025003
Publications 2018
Trauma-related altered states of consciousness in post-traumatic stress disorder patients with or without comorbid dissociative disorders
Eur J Psychotraumatol, 9 (1), 1544025
DOI 10.1080/20008198.2018.1544025, PubMed 30455853
Measuring cognitive impairment in young adults with polysubstance use disorder with MoCA or BRIEF-A - The significance of psychiatric symptoms
J Subst Abuse Treat, 97, 21-27
DOI 10.1016/j.jsat.2018.11.010, PubMed 30577896
The LASSO Program in Oslo: Harm Reduction Using Buprenorphine-Naloxone (Suboxone®) in a Low Threshold Setting
Eur Addict Res, 24 (6), 286-292
DOI 10.1159/000495188, PubMed 30466108
Inmates with Harmful Substance Use Increase Both Exercise and Nicotine Use Under Incarceration
Int J Environ Res Public Health, 15 (12)
DOI 10.3390/ijerph15122663, PubMed 30486386
Cardiometabolic risk factors, physical activity and psychiatric status in patients in long-term psychiatric inpatient departments
Nord J Psychiatry, 72 (4), 296-302
DOI 10.1080/08039488.2018.1449012, PubMed 29523041
Using motivational techniques to reduce cardiometabolic risk factors in long term psychiatric inpatients: a naturalistic interventional study
BMC Psychiatry, 18 (1), 255
DOI 10.1186/s12888-018-1832-6, PubMed 30111298
Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial
Addiction, 113 (10), 1840-1849
DOI 10.1111/add.14278, PubMed 29806872
Publications 2017
The Kühtai data set: 25 years of lysimetric, snow pillow, and meteorological measurements
Water Resour Res, 53 (6), 5158-5165
DOI 10.1002/2017WR020445, PubMed 28931957
Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial
JAMA Psychiatry, 74 (12), 1197-1205
DOI 10.1001/jamapsychiatry.2017.3206, PubMed 29049469
Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model
Eur J Gastroenterol Hepatol, 29 (11), 1206-1214
DOI 10.1097/MEG.0000000000000962, PubMed 28914697
Publications 2016
Autism Spectrum Disorder and Co-occurring Substance Use Disorder - A Systematic Review
Subst Abuse, 10, 69-75
DOI 10.4137/SART.S39921, PubMed 27559296
Psychosis induced by amphetamines
Curr Opin Psychiatry, 29 (4), 236-41
DOI 10.1097/YCO.0000000000000254, PubMed 27175554
Will non-compliant 'hard-to-treat' opioid-dependent patients profit from low threshold methadone treatment? A prospective 15-month evaluation of patients on Low Dosage Methadone treatment at Oslo University Hospital
Heroin Addict. Relat. Clin. Probl., 18 (3), 23-27
More Than Just a Break from Treatment: How Substance Use Disorder Patients Experience the Stable Environment in Horse-Assisted Therapy
Subst Abuse, 10, 99-108
DOI 10.4137/SART.S40475, PubMed 27746677
Contribution of the patient-horse relationship to substance use disorder treatment: Patients' experiences
Int J Qual Stud Health Well-being, 11, 31636
DOI 10.3402/qhw.v11.31636, PubMed 27291162
Assessment of personality problems among patients with substance use disorders
Nord. Stud. Alcohol Drugs, 33 (4), 399-414
DOI 10.1515/nsad-2016-0033
Buprenorphine dosing choices in specific populations: review of expert opinion
Expert Opin Pharmacother, 17 (13), 1727-31
DOI 10.1080/14656566.2016.1209486, PubMed 27376622
Young adults' reasons for dropout from residential substance use disorder treatment
Qual Soc Work, 17 (1), 24-40
DOI 10.1177/1473325016654559, PubMed 29276430
Substance use and sociodemographic background as risk factors for lifetime psychotic experiences in a non-clinical sample
J Subst Abuse Treat, 74, 42-47
DOI 10.1016/j.jsat.2016.12.007, PubMed 28132699
Publications 2015
The extent of misuse and diversion of medication for agonist opioid treatment: A review and expert opinions
Heroin Addict. Relat. Clin. Probl., 17 (2-3), 25-33
Misuse and diversion of agonist opioid treatment medicines: assessment of the scale of the problem and review of the changing environment for care in the Nordic countries
Heroin Addict. Relat. Clin. Probl., 17 (5), 43-49
The Norwegian Offender Mental Health and Addiction Study - Design and Implementation of a National Survey and Prospective Cohort Study
Subst Abuse, 9 (Suppl 2), 59-66
DOI 10.4137/SaRt.S23546, PubMed 26648732
Substance use disorder treatment retention and completion: a prospective study of horse-assisted therapy (HAT) for young adults
Addict Sci Clin Pract, 10, 21
DOI 10.1186/s13722-015-0043-4, PubMed 26466788
Amphetamine-induced psychosis: Transition to schizophrenia and mortality in a small prospective sample
Am J Addict, 24 (7), 586-9
DOI 10.1111/ajad.12274, PubMed 26332037
Effects of Hemodialysis on Methadone Pharmacokinetics and QTc
Clin Ther, 37 (7), 1594-9
DOI 10.1016/j.clinthera.2015.04.009, PubMed 25963997
The Impact of Misuse and Diversion of Opioid Substitution Treatment Medicines: Evidence Review and Expert Consensus
Eur Addict Res, 22 (2), 99-106
DOI 10.1159/000438988, PubMed 26426530
Long-term risk factors for substance-induced and primary psychosis after release from prison. A longitudinal study of substance users
Schizophr Res, 168 (1-2), 185-90
DOI 10.1016/j.schres.2015.08.032, PubMed 26359848
[Amphetamine-induced psychosis or schizophrenia?]
Tidsskr Nor Laegeforen, 135 (3), 249-51
DOI 10.4045/tidsskr.14.1365, PubMed 25668544
Manual-based cognitive behavioral and cognitive rehabilitation therapy for young-onset dementia: a case report
Int Psychogeriatr, 28 (3), 519-22
DOI 10.1017/S1041610215001696, PubMed 26552831
Challenges With Manual-Based Multimodal Psychotherapy for People With Alzheimer's Disease: A Case Study
Am J Alzheimers Dis Other Demen, 31 (4), 311-7
DOI 10.1177/1533317515603958, PubMed 26385947
Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience
J Public Health (Oxf), 38 (3), e368-e374
DOI 10.1093/pubmed/fdv150, PubMed 26508767
Publications 2014
Does the pattern of amphetamine use prior to incarceration predict later psychosis?--a longitudinal study of amphetamine users in the Swedish criminal justice system
Drug Alcohol Depend, 143, 219-24
DOI 10.1016/j.drugalcdep.2014.07.037, PubMed 25146382
Publications 2013
Psychometric properties of the outcome questionnaire-45.2: the Norwegian version in an international context
Psychother Res, 24 (4), 504-13
DOI 10.1080/10503307.2013.849016, PubMed 24188797
Health service costs and clinical gains of psychotherapy for personality disorders: a randomized controlled trial of day-hospital-based step-down treatment versus outpatient treatment at a specialist practice
BMC Psychiatry, 13, 315
DOI 10.1186/1471-244X-13-315, PubMed 24268099
Publications 2012
Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?
BMC Psychiatry, 12, 221
DOI 10.1186/1471-244X-12-221, PubMed 23216941
Publications 2010
Psychotherapy for personality disorders: 18 months' follow-up of the ullevål personality project
J Pers Disord, 24 (2), 188-203
DOI 10.1521/pedi.2010.24.2.188, PubMed 20420475
Publications 2009
A cross-national validity study of the Severity Indices of Personality Problems (SIPP-118)
Personal. Ment. Health, 3 (1), 41-55
DOI 10.1002/pmh.60
Publications 2008
Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study
Eur Psychiatry, 24 (2), 71-8
DOI 10.1016/j.eurpsy.2008.09.004, PubMed 19097870
Publications 2005
Histopathological grading of laryngectomy specimens
APMIS, 113 (7-8), 473-88
DOI 10.1111/j.1600-0463.2005.apm_24.x, PubMed 16086817
Publications 2004
Laryngectomy whole organ serial sections--histological parameters correlated with recurrence rate
Acta Oncol, 43 (1), 98-107
DOI 10.1080/02841860310020366, PubMed 15068327
Publications 2002
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
N Engl J Med, 346 (25), 1937-47
DOI 10.1056/NEJMoa012914, PubMed 12075054
Publications 2000
[Pseudo-Meigs' syndrome]
Tidsskr Nor Laegeforen, 120 (3), 364-6
PubMed 10827530
Publications 1999
Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice
J Exp Med, 190 (7), 915-22
DOI 10.1084/jem.190.7.915, PubMed 10510081
Different regulatory pathways employed in cytokine-enhanced expression of secretory component and epithelial HLA class I genes
Eur J Immunol, 29 (1), 168-79
DOI 10.1002/(SICI)1521-4141(199901)29:01<168::AID-IMMU168>3.0.CO;2-8, PubMed 9933098
Domain deletions in the human polymeric Ig receptor disclose differences between its dimeric IgA and pentameric IgM interaction
Eur J Immunol, 29 (10), 3401-9
DOI 10.1002/(SICI)1521-4141(199910)29:10<3401::AID-IMMU3401>3.0.CO;2-G, PubMed 10540352
Publications 1998
A composite DNA element in the promoter of the polymeric immunoglobulin receptor regulates its constitutive expression
Eur J Immunol, 28 (4), 1161-71
DOI 10.1002/(SICI)1521-4141(199804)28:04<1161::AID-IMMU1161>3.0.CO;2-S, PubMed 9565355
Publications 1997
Modulation of disease severity of dystrophic epidermolysis bullosa by a splice site mutation in combination with a missense mutation in the COL7A1 gene
Hum Mol Genet, 6 (7), 1125-35
DOI 10.1093/hmg/6.7.1125, PubMed 9215684
Publications 1996
Secretory component mRNA and protein expression in colorectal adenomas and carcinomas
Br J Cancer, 73 (12), 1503-10
DOI 10.1038/bjc.1996.284, PubMed 8664120
Publications 1995
The enterocyte and immunoglobulin transport
Dyn.Nutr.Res., 4, 1-17
Antibody production to secretory component (SC) using recombinant SC fragment
Adv Exp Med Biol, 371A, 633-5
DOI 10.1007/978-1-4615-1941-6_133, PubMed 8526006
Cloning, chromosomal localization, and linkage analysis of the gene encoding human transmembrane secretory component (the poly-Ig receptor)
Adv Exp Med Biol, 371A, 617-23
DOI 10.1007/978-1-4615-1941-6_130, PubMed 8526003
Cloning and characterization of two forms of bovine polymeric immunoglobulin receptor cDNA
DNA Cell Biol, 14 (3), 251-6
DOI 10.1089/dna.1995.14.251, PubMed 7880445
Expression of SC, IL-6 and TGF-beta 1 in epithelial cell lines
Adv Exp Med Biol, 371A, 175-82
DOI 10.1007/978-1-4615-1941-6_36, PubMed 8525901
Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma
Gut, 37 (6), 766-76
DOI 10.1136/gut.37.6.766, PubMed 8537046
Intestinal perforation after ingestion of a blister-wrapped tablet
Lancet, 346 (8985), 1308
DOI 10.1016/s0140-6736(95)91918-x, PubMed 7475762
Publications 1993
Interferon-gamma stimulation of messenger RNA for human secretory component (poly-Ig receptor) depends on continuous intermediate protein synthesis
Scand J Immunol, 37 (2), 251-6
DOI 10.1111/j.1365-3083.1993.tb01763.x, PubMed 8434236
Publications 1992
Epithelial expression of HLA, secretory component (poly-Ig receptor), and adhesion molecules in the human alimentary tract
Ann N Y Acad Sci, 664, 157-79
DOI 10.1111/j.1749-6632.1992.tb39758.x, PubMed 1456647
EPITHELIAL EXPRESSION OF HLA, SECRETORY COMPONENT (POLY-IG RECEPTOR), AND ADHESION MOLECULES IN THE HUMAN ALIMENTARY-TRACT
Ann.NY Acad.Sci., 664, 157-179
DOI 10.1111/j.1749-6632.1992.tb39758.x
The gene encoding human transmembrane secretory component (locus PIGR) is linked to D1S58 on chromosome 1
Hum Genet, 90 (3), 215-9
DOI 10.1007/BF00220065, PubMed 1487233
Molecular cloning and exon-intron mapping of the gene encoding human transmembrane secretory component (the poly-Ig receptor)
Eur J Immunol, 22 (9), 2309-15
DOI 10.1002/eji.1830220920, PubMed 1355431
Expression and regulation of adhesion molecules ICAM-1 (CD54) and LFA-3 (CD58) in human intestinal epithelial cell lines
Scand J Immunol, 35 (6), 669-76
DOI 10.1111/j.1365-3083.1992.tb02973.x, PubMed 1376489
Mapping of the regulatory subunits RI beta and RII beta of cAMP-dependent protein kinase genes on human chromosome 7
Genomics, 14 (1), 63-9
DOI 10.1016/s0888-7543(05)80284-8, PubMed 1358799
Publications 1991
The human transmembrane secretory component (poly-Ig receptor): molecular cloning, restriction fragment length polymorphism and chromosomal sublocalization
Hum Genet, 87 (6), 642-8
DOI 10.1007/BF00201717, PubMed 1682231
Publications 1989
Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes
Gastroenterology, 97 (6), 1562-84
DOI 10.1016/0016-5085(89)90406-x, PubMed 2684725
Molecular cloning of the human transmembrane secretory component (poly-Ig receptor) and its mRNA expression in human tissues
Biochem Biophys Res Commun, 158 (3), 783-9
DOI 10.1016/0006-291x(89)92790-3, PubMed 2920039
Publications 1986
The fate of epidermal colcemid-arrested mitoses
Virchows Arch B Cell Pathol Incl Mol Pathol, 51 (2), 115-26
DOI 10.1007/BF02899022, PubMed 2873676